Pulsenmore Secures First U.S. Commercial Deal for Home Ultrasound
Event summary
- Pulsenmore Ltd. signed its first commercial agreement in the U.S. with the Center for Fetal Medicine & Women's Ultrasound (CFFM) in Los Angeles.
- The deal follows Pulsenmore's FDA approval for its home pregnancy ultrasound product in January 2026.
- CFFM will purchase Pulsenmore ES home ultrasound services to enable remote monitoring for patients.
- CFFM manages approximately 1,500 pregnancies annually and specializes in high-risk obstetric care.
The big picture
Pulsenmore's first U.S. commercial deal marks a strategic milestone in its expansion into the digital health and telemedicine sectors. The agreement with CFFM underscores the growing demand for remote prenatal monitoring solutions, particularly in high-risk obstetric care. This deal positions Pulsenmore to capitalize on the increasing need for patient-centric, high-quality care delivered beyond traditional clinical settings.
What we're watching
- Market Adoption
- How quickly Pulsenmore can scale its home ultrasound services across other U.S. medical centers.
- Regulatory Compliance
- Whether Pulsenmore can maintain regulatory compliance as it expands into new markets.
- Competitive Positioning
- The pace at which Pulsenmore can differentiate itself in the growing digital health and telemedicine sectors.
Related topics